Global Information
회사소개 | 문의 | 비교리스트

세계의 전립선 비대증(BPH) 치료 시장(2019-2025년)

Benign Prostatic Hyperplasia Treatment Market 2019-2025

리서치사 Orion Market Research Pvt Ltd
발행일 2020년 06월 상품 코드 949544
페이지 정보 영문
가격
US $ 3,600 ₩ 4,054,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,406,000 Printable PDF (Enterprise License)


세계의 전립선 비대증(BPH) 치료 시장(2019-2025년) Benign Prostatic Hyperplasia Treatment Market 2019-2025
발행일 : 2020년 06월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 전립선 비대증(BPH) 치료 시장은 예측기간 중 대폭적인 CAGR로 성장할 것으로 추정됩니다. 중년 인구 사이에서 전립선 비대증(BPH)이 빈발하고 있는 점이 시장 성장을 촉진하고 있습니다. BPH는 51-60세 남성의 약 50% 및 80세 이상 남성의 90%에 영향을 미칩니다. 또한 시장 성장을 촉진하는 주요 요인으로 경제 성장과 공공·정부의 인식을 들 수 있습니다. 미국의 건강옹호단체와 보건 당국은 매년 9월에 "National Prostate Health Month"라는 전립선 건강 계발 캠페인을 실시하고, 양성 전립선 비대증과 관련된 위험과 치료에 대해 사람들에게 교육하고 있습니다.

세계의 전립선 비대증(BPH) 치료 시장에 대해 조사 분석했으며, 시장 개요, 시장 성장에 대한 영향요인, 시장 규모와 예측, 부문별 시장 분석, 지역·국가별 시장 분석, 경쟁 상황 등에 대한 체계적인 정보를 제공합니다.

목차

제1장 보고서 개요

제2장 시장 개요 및 인사이트

  • 조사 범위
  • 애널리스트의 견해와 현재 시장 동향

제3장 경쟁 상황

  • 기업 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석
    • Allergan PLC
    • Eli Lilly and Company
    • Merck&Co., Inc.
    • Lumenis, Ltd.
    • Olympus Corp.
    • Karl Storz GmbH&Co.Kg

제4장 시장 결정요인

  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제5장 시장 세분화

  • 세계의 전립선 비대증(BPH) 치료 시장 : 치료별
    • 약물요법
    • 최소침습 수술
    • 레이저 치료
    • 기타(외과, 인공 요도 리프트, 색전술)

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타 아시아태평양
  • 기타 지역

제7장 기업 개요

  • Abbott Laboratories
  • Allergan, Inc.
  • Astellas Pharma, Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corp.
  • Camber Pharmaceuticals, Inc.
  • Coloplast A/S
  • Daiichi Sankyo Co., Ltd.
  • Eli Lilly &Co.
  • Endo International PLC
  • GlaxoSmithKline PLC
  • Karl Storz GmbH& Co.Kg
  • Lumenis, Ltd.
  • Merck & Co., Inc.
  • Nymox Pharmaceutical Corp.
  • Olympus Corp.
  • Pfizer, Inc.
  • ProArc Medical, Ltd.
  • Sanofi S.A.
  • Sophiris Bio Corp.
  • Sun Pharmaceutical Industries, Ltd.
  • Synthon B.V.
  • Teva Pharmaceutical Industries, Ltd.
  • Urologix, Inc.
  • Veru, Inc.
KSM 20.08.07

LIST OF TABLES

  • 1. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)

2. GLOBAL MEDICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($, MILLION)

  • 3. GLOBAL MINIMALLY INVASIVE PROCEDURE MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL LASER THERAPY MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 5. GLOBAL OTHER TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENTMARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 7. NORTH AMERICAN BENIGN PROSTATIC HYPERPLASIA TREATMENTMARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 8. NORTH AMERICAN BENIGN PROSTATIC HYPERPLASIA TREATMENTMARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 9. EUROPEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 10. EUROPEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 11. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 12. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)
  • 13. REST OF THE WORLD BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2018-2025 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENTMARKET SHARE BY TREATMENT, 2018 VS 2025 (%)
  • 2. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENTMARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 3. US BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 4. CANADA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. UK GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. FRANCE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. GERMANY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. ITALY BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. SPAIN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. ROE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. INDIA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. JAPAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF THE WORLD BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2025 ($ MILLION)

Global Benign Prostatic Hyperplasia Treatment Market Size, Share & Trends Analysis Report, by Treatment (Medications {Alpha-blockers, 5 Alpha reductase inhibitor (ARIs), Phosphodiesterase-5 Enzyme Inhibitor, and Others}, Minimally Invasive Procedures {TURP, TUIP, TUMT, and TUNA}, Laser Therapy {Ablative procedures and Enucleation procedures}, and Others) and Forecast Period 2019-2025

The global benign prostatic hyperplasia treatment market is estimated to grow at a significant CAGR during the forecast period. The rising frequency of benign prostatic hyperplasia among middle-aged people is driving the market. BPH affects nearly 50% of men between the ages of 51-60 and 90% of men age above 80. Moreover, some crucial factors attributing to the positive growth of the market, that are economic growth and public & government awareness. The US health advocate and health authorities conduct prostate health awareness campaign the "National Prostate Health Month" every year in September, to educate the people about the risk and treatment that are associates with benign prostatic hyperplasia.

The global benign prostatic hyperplasia treatment market is segmented based on treatment type. Based on the treatment type, the market is segmented into medications, minimally invasive procedures, laser therapy, and others. Based on medications, it is segmented into alpha-blockers, 5 alpha-reductase inhibitors (ARIs), a phosphodiesterase-5 enzyme inhibitor, and others. Based on minimally invasive procedures, it is segmented into transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave thermotherapy (TUMT), and Transurethral Needle Ablation (TUNA). Based on laser therapy, it is segmented into ablative procedures and enucleation procedures.Based on geography, the market is classified into four major regions, including North America, Europe, Asia-Pacific, and RoW.

The key players providing benign prostatic hyperplasia treatmentproducts include Allergan PLC, Eli Lilly, and Co., Merck & Co., Inc., Abbott Laboratories, Allergan, Inc., Astellas Pharma, Inc., Pfizer, Inc., Sanofi S.A., Karl Storz GmbH& Co.Kg, Lumenis,Ltd., Olympus Corporation, Boston Scientific Corp., and others. The strategies adopted by the market players include joint venture and product launches, to increase their competitiveness across a global scale. For instance, in May 2019, Lumenis Ltd. launched MOSES for BPH procedures. This device optimizes holmium energy transmission using pulse modulation. This technology also added to Holmium Laser Enucleation of the Prostate (HoLEP)

Research Methodology

The market study of the global benign prostatic hyperplasia treatment market is incorporated by extensive primary and secondary research conducted by a research team. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Reports of companies involved in the market
  • Authentic public databases
  • Whitepapers such as research papers and news blogs
  • Company websites and their product catalog

The report is intended for providers, suppliers, and distributors of benign prostatic hyperplasia treatment, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and will serve as a source for 360-degree analysis of the market.

The Report Covers:

  • Comprehensive research methodology of the global benign prostatic hyperplasia treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Insights about market determinants which are stimulating the global benign prostatic hyperplasia treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusions

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Allergan PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Eli Lilly and Company
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Merck & Co., Inc.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Lumenis, Ltd.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Olympus Corp.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments
    • 3.3.6. Karl Storz GmbH& Co.Kg
      • 3.3.6.1. Overview
      • 3.3.6.2. Financial Analysis
      • 3.3.6.3. SWOT Analysis
      • 3.3.6.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Benign Prostatic Hyperplasia Treatment Marketby Treatment
    • 5.1.1. Medications
      • 5.1.1.1. Alpha-blockers
      • 5.1.1.2. 5 Alpha reductase inhibitor (ARIs)
      • 5.1.1.3. Phosphodiesterase-5 Enzyme Inhibitor
      • 5.1.1.4. Others
    • 5.1.2. Minimally Invasive Procedures
      • 5.1.2.1. Transurethral Resection of the Prostate (TURP)
      • 5.1.2.2. Transurethral Incision of the Prostate (TUIP)
      • 5.1.2.3. Transurethral Microwave Thermotherapy (TUMT)
      • 5.1.2.4. Transurethral Needle Ablation (TUNA)
    • 5.1.3. Laser Therapy
      • 5.1.3.1. Ablative procedures
      • 5.1.3.2. Enucleation procedures
    • 5.1.4. Others (Surgery, Prothetic urethral lift, Embolization)

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Allergan, Inc.
  • 7.3. Astellas Pharma, Inc.
  • 7.4. Boehringer Ingelheim GmbH
  • 7.5. Boston Scientific Corp.
  • 7.6. Camber Pharmaceuticals, Inc.
  • 7.7. Coloplast A/S
  • 7.8. Daiichi Sankyo Co., Ltd.
  • 7.9. Eli Lilly &Co.
  • 7.10. Endo International PLC
  • 7.11. GlaxoSmithKline PLC
  • 7.12. Karl Storz GmbH& Co.Kg
  • 7.13. Lumenis, Ltd.
  • 7.14. Merck & Co., Inc.
  • 7.15. Nymox Pharmaceutical Corp.
  • 7.16. Olympus Corp.
  • 7.17. Pfizer, Inc.
  • 7.18. ProArc Medical, Ltd.
  • 7.19. Sanofi S.A.
  • 7.20. Sophiris Bio Corp.
  • 7.21. Sun Pharmaceutical Industries, Ltd.
  • 7.22. Synthon B.V.
  • 7.23. Teva Pharmaceutical Industries, Ltd.
  • 7.24. Urologix, Inc.
  • 7.25. Veru, Inc.
Back to Top
전화 문의
F A Q